home / stock / cntb / cntb articles
Connect Biopharma Holdings Limited (NASDAQ: CNTB) released topline results from Stage 2 (maintenance period) of its China pivotal trial evalua...
Shares of Symbotic Inc. (NASDAQ: SYM) surged in pre-market trading after the company reported better-than-expected fourth-quarter sales results. T...
Clinical response (IGA 0/1 and EASI-75) achieved at Week 16 with rademikibart treatment was maintained through Week 52 with both every two weeks ...
Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholder...
Gainers Orchard Therapeutics plc (NASDAQ: ORTX) shares climbed 97.7% to $15.98 after the company agreed to be acquired by Japan's Kyowa Kirin...
News, Short Squeeze, Breakout and More Instantly...
Connect Biopharma Holdings Limited Company Name:
CNTB Stock Symbol:
NASDAQ Market:
SAN DIEGO, CA and TIACANG, China, July 01, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases thr...
SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases thr...
Rademikibart treatment significantly improved lung function at Week 12; improvements were observed as early as Week 1 and sustained through Week 24 Significant improvement in patient-reported asthma control occurred early and was sustained through Week 24 End of Phase 2 (EoP2) meeting i...